文献リスト

1）Wada H. Disseminated intravascular coagulation. Clin Chim Acta. 2004; 344: 13-21

2）日本血栓止血学会学術標準化委員会DIC部会．科学的根拠に基づいた感染症に伴うDIC治療のエキスパートコンセンサス．日本血栓止血学会誌．2009; 20: 77-113

3）Wada H, Asakura H, Okamoto K, et al. Japanese Society of Thrombosis Hemostasis/DIC subcommittee: Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res. 2010; 125: 6-11

4）Levi M, Toh CH, Thachil J, et al. Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol. 2009; 145: 24-33

5）Di Nisio M, Baudo F, Cosmi B, et al; on behalf of the Italian Society for Thrombosis and Haemostasis. Diagnosis and treatment of disseminated intravascular coagulation: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res. 2012; 129: e177-84

6）Wada H, Thachil J, Di Nisio M, et al; The Scientific Standardization Committee on DIC of the International Society on Thrombosis Haemostasis. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost. 2013; 11: 761-7

7）Wada H, Matsumoto T, Yamashita Y, et al. Disseminated intravascular coagulation: Testing and diagnosis. Clin Chim Acta. 2014; 436C: 130-4

8）Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 2004; 303: 1532-5

9）Gando S, Saitoh D, Ogura H, et al. A multicenter, prospective validation study of the Japanese Association for Acute Medicine disseminated intravascular coagulation scoring system in patients with severe sepsis. Crit Care. 2013; 17: R111

10）Gando S, Saitoh D, Ogura H, et al. Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: results of a multicenter, prospective survey. Crit Care Med. 2008; 36: 145-50

11）Wada H, Matsumoto T, Yamashita Y, et al. Is early treatment of DIC beneficial in septic patients? Crit Care. 2014; 18: 44

12）Wiedermann CJ, Kaneider NC. A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis. Blood Coagul Fibrinolysis. 2006; 17: 521-6

13）Minneci PC, Deans KJ, Cui X, et al. Antithrombotic therapies for sepsis: a need for more studies. Crit Care Med. 2006; 34: 538-41

14）Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002; 347: 589-600

15）Sakuma M, Konno Y, Shirato K. Increasing mortality from pulmonary embolism in Japan, 1951-2000. Circ J. 2002; 66: 1144-9

16）Wada H. Disseminated intravascular coagulation. Clin Chim Acta. 2004; 344: 13-21

17）Wada H, Matsumoto T, Hatada T. Diagnostic criteria and laboratory tests for disseminated intravascular coagulation. Expert Rev Hematol. 2012; 5: 643-52

18）Matsumoto M, Bennett CL, Isonishi A, et al. Acquired idiopathic ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in a population from Japan. PLoS One. 2012; 7: e33029

19）Ono T, Mimuro J, Madoiwa S, et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood. 2006; 107: 528-34

20）Warren BL, Eid A, Singer P, et al. High-dose antithrombin in severe sepsis. A randomized controlled trial. JAMA. 2001; 286: 1869-78

21）Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human protein C for severe sepsis. N Engl J Med. 2001; 8: 699-709

22）Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007; 5: 31-41

23）Fuchs TA, Brill A, Duerschmied D, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A. 2010; 107: 15880-5

24）Massberg S, Grahl L, von Bruehl ML, et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med. 2010; 16: 887-96

25）Hatada T, Wada H, Nobori T, et al. Plasma concentrations and importance of high mobility group box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost. 2005; 94: 975-9

26）Wada H, Wakita Y, Nakase T, et al. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Thromb Haemost. 1995; 74: 848-52

27）Kobayashi N, Maegawa T, Takada M, et al. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan. Bibl Haemotol. 1983; 49: 265-75

28）Taylor Jr FB, Toh CH, Hoots WK, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation - On behalf of the Scientific Subcommittee on disseminated intravascular coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Thromb Haemost. 2001; 86: 1327-30

29）Gando S, Iba T, Eguchi Y, et al; Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med. 2006; 34: 625-31

30）Okamoto K, Wada H, Hatada T, et al. Japanese Society of Thrombosis Hemostasis/DIC subcommittee: Frequency and hemostatic abnormalities in pre-DIC patients. Thromb Res. 2010; 126: 74-8

31）Wada H, Hatada T, Okamoto K, et al. Modified non-overt DIC diagnostic criteria predict the early phase of overt-DIC. Am J Hematol. 2010; 85: 691-4

32）Takemitsu T, Wada H, Hatada T, et al. Prospective evaluation of three different diagnostic criteria for disseminated intravascular coagulation. Thromb Haemost. 2011; 105: 40-4

33）Kawasugi K, Wada H, Hatada T, et al; Japanese Society of Thrombosis Hemostasis/DIC subcommittee. Prospective evaluation of hemostatic abnormalities in overt DIC due to various underlying diseases. Thromb Res. 2011; 128: 186-90

34）Hatada T，Wada H, Kawasugi K, et al. Analysis of the cut-off values in fibrin related markers for the diagnosis of overt DIC. Clin Appl Thromb Hemost. 2012; 18: 495-500

35）Seki Y, Wada H, Kawasugi K, et al; Japanese Society of Thrombosis Hemostasis/DIC Subcommittee. A prospective analysis of disseminated intravascular coagulation in patients with infections. Intern Med. 2013; 52: 1893-8

36）Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003; 290: 238-47

37）Toh CH, Hoots WK. The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview. J Thromb Haemost. 2007; 5: 604-6

38）Hayakawa M, Gando S, Hoshino H. A prospective comparison of new Japanese criteria for disseminated intravascular coagulation: New Japanese criteria versus ISTH criteria. Clin Appl Thromb Hemost. 2007; 13: 172-81

39）Egi M, Morimatsu H, Wiedermann CJ, et al. Non-overt disseminated intravascular coagulation scoring for critically ill patients: The impact of antithrombin levels. Thromb Haemost. 2009; 101: 696-705

40）Oh D, Jang MJ, Lee SJ, et al. Evaluation of modified non-overt DIC criteria on the prediction of poor outcome in patients with sepsis. Thromb Res. 2010; 126: 18-23

41）朝倉英策，高橋芳右，内山俊正，他．日本血栓止血学会DIC診断基準暫定案．日本血栓止血学会誌．2014; in press

42）Ishikura H, Nishida T, Murai A, et al. New diagnostic strategy for sepsis-induced disseminated intravascular coagulation: a prospective single-center observational study. Crit Care. 2014; 18: R19

43）Polderman KH, Girbes ARJ. Drug intervention trials in sepsis: divergent results. Lancet. 2004; 363: 1721-3

44）Aikawa N, Shimazaki S, Yamamoto Y, et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock. 2011; 35: 349-54

45）Vincent JL, Ramesh MK, Ernest D, et al. A randomized, double-blind, placebo-controlled, phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med. 2013; 41: 2069-79

46）Mimuro J, Takahashi H, Kitajima I, et al. Impact of recombinant soluble thrombomodulin (thrombomodulin alfa) on disseminated intravascular coagulation. Thromb Res. 2013; 131: 436-43

47）和田英夫，坂田洋一，丸藤　哲，他．科学的根拠に基づいた感染症に伴うDIC治療のエキスパートコンセンサスの追補．日本血栓止血学会誌．2014; 25: 123-5

48）Wada H, Okamoto K, Iba T, et al. Addition of recommendations for the use of recombinant human thrombomodulin to the “Expert consensus for the treatment of disseminated intravascular coagulation in Japan”. Thromb Res. 2014, in press

49）Gando S, Saitoh D, Ishikura H, et al. A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Crit Care. 2013; 17: R297

50）Iba T, Saito D, Wada H, et al. Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: A prospective multicenter survey. Thromb Res. 2012; 130: e129-33

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp